Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | NPBWR1 | P48145 | 5/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.43 |
| ▸ | XBP1 | P17861 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4060284 | 0.80 | RAB9A (0.47) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1NPBWR1 | |
| SCHEMBL1749799 | 0.79 | RAB9A (0.54) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1NPBWR1 | |
| SCHEMBL1751460 | 0.79 | RAB9A (0.62) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1NPBWR1 | |
| SCHEMBL1750161 | 0.76 | NPBWR1 (0.43) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1NPBWR1 | |
| SCHEMBL14385181 | 0.72 | RAB9A (0.55) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL4498149 | 0.72 | RAB9A (0.55) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL13219324 | 0.71 | ALDH1A1 (0.66) | RAB9ASMN1; SMN2ALDH1A1NPBWR1MCHR1 | |
| SCHEMBL11635867 | 0.70 | ALDH1A1 (0.55) | RAB9ASMN1; SMN2L3MBTL1ALDH1A1NPBWR1 | |
| SCHEMBL1751014 | 0.70 | NPBWR1 (0.56) | RAB9ASMN1; SMN2ALDH1A1NPBWR1MCHR1 | |
| SCHEMBL7910204 | 0.70 | NPBWR1 (0.49) | RAB9ASMN1; SMN2ALDH1A1NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | claimed |
| US-7968711-B2 | Isoprenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol, 2-(3,5-Difluorophenyl)-5-hydroxypyridazin-3-one, 4-Bromo-2-(2,5-dichlorophenyl)-5-hydroxypyridazin-3-one; glaucoma or ocular hypertension | ALLERGAN, INC. (US) | 2011-06-28 | — | — | US | claimed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | disclosed |
| US-7968711-B2 | Isoprenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol, 2-(3,5-Difluorophenyl)-5-hydroxypyridazin-3-one, 4-Bromo-2-(2,5-dichlorophenyl)-5-hydroxypyridazin-3-one; glaucoma or ocular hypertension | ALLERGAN, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2123264-A1 | Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2010165-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007127711-A2 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249596-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | RAB9A 342/4885SMN1; SMN2 4837/4885L3MBTL1 4422/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | RAB9A 342/4885SMN1; SMN2 4837/4885L3MBTL1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.